Fulranumab for treatment of diabetic peripheral neuropathic pain: A randomized controlled trial

OBJECTIVE: To assess efficacy and safety of fulranumab, a fully human monoclonal antibody against nerve growth factor, in patients with diabetic peripheral neuropathic pain (DPNP). METHODS: In this phase II, double-blind, placebo-controlled trial, patients with moderate to severe DPNP were randomize...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Wang, Hao, Romano, Gary, Frustaci, Mary Ellen, Bohidar, Norm, Ma, Huizhong, Sanga, Panna, Ness, Seth, Russell, Lucille J., Fedgchin, Margaret, Kelly, Kathleen M., Thipphawong, John
פורמט: Artigo
שפה:Inglês
יצא לאור: Lippincott Williams & Wilkins 2014
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4141990/
https://ncbi.nlm.nih.gov/pubmed/25008392
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0000000000000686
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים